CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 9 No. 7
 

Medicare to Cover Beneficiaries’ Routine Care in Clinical Trials

July 1, 2000

WASHINGTON—President Clinton has ordered Medicare to begin paying for the routine care of all its beneficiaries who participate in clinical trials. The president also directed that the Department of Health and Human Services (HHS) take other actions to promote the participation of older patients in clinical trials.

Until the president issued his executive memorandum directing a policy revision, Medicare policies discouraged recipients from taking part in clinical trials. As a result, providers and patients could not be certain that Medicare would reimburse the costs of care that is routinely covered when a patient receives the standard treatment for a disease, although it often did.

In announcing the President’s decision, the White House cited a recent Institute of Medicine report that urged policy changes to increase the participation of older Americans in clinical trials. It also noted the bipartisan support for legislation pending on Capitol Hill that would ensure coverage of routine care for Medicare patients who participate in such trials.

According to a White House statement, only about 1% of older Americans take part in clinical testing. For example, 63% of cancer patients are age 65 years or older, but this age group constitutes only 33% of enrollees in clinical trials. Among older women with breast cancer, the disparity is even sharper; 44% of breast cancer patients are 65 or older, but only 1.6% are entered into clinical trials.

“These low participation rates hinder development of new therapies, as it often takes between 3 and 5 years to enroll enough participants in a trial,” Medicare’s Jeffrey Kang, MD, told the House Committee on Government Reform on the day the President’s directive was announced.

Dr. Kang, director of the Health Care Financing Administration (HCFA) Office of Standards and Quality, said that Medicare historically did not cover clinical trials “because they did not meet the requirement of being reasonable and necessary.”

However, he added, in response to the President’s directive, Medicare “will move quickly to implement this new policy by formally and explicitly instructing our contractors to provide such coverage.” In his executive memorandum, Mr. Clinton also directed the HHS to:

  • Initiate a campaign to inform Medicare patients of the new clinical trials coverage option.

  • Establish a system to track spending in trials that Medicare helps support.

  • Ensure that information gained from important clinical trials is used in making coverage decisions.

  • Evaluate the feasibility and advisability of taking additional action to increase the participation of older Americans in clinical trials as a way to assess the best therapies for that age group.

  • Develop a registry of ongoing clinical trials receiving Medicare reimbursement.

To help guide Medicare coverage, the White House said that HCFA and the National Institutes of Health will work with researchers prior to the beginning of a clinical trial that has significant implications for the Medicare program. The goal is to structure such trials in a way that will provide information useful to HCFA in making coverage decisions.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy